Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amlodipine + botulinum toxin
- Development stage
- Preclinical
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intramuscular
01
Overview
A combination therapy being investigated where amlodipine (a calcium channel blocker) is used to potentially augment the effects of botulinum toxin injections in the treatment of focal dystonia. Botulinum toxin works by blocking nerve signals that cause muscles to contract, resulting in muscle relaxation. Amlodipine belongs to a class of medications called calcium channel blockers that relax blood vessels. The combination is being studied to determine if amlodipine can enhance the therapeutic effects of botulinum toxin in patients with focal dystonia.
02
Targets
LTCC (Voltage-gated calcium channel (L-type))CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)VAMP (SNARE Protein Complex)
Beyond the preview
Go deeper on amlodipine + botulinum toxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amlodipine + botulinum toxin.